Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE, Individualized Neoantigen Vaccine for Solid Tumors
15 août 2022 16h05 HE
|
Gritstone bio
-- Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells, including cytotoxic CD8+ T cells -- -- T cells linked to...
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors
10 août 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
04 août 2022 16h05 HE
|
Gritstone bio
-- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program (CORAL) expected this year...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 juil. 2022 07h00 HE
|
Gritstone bio
EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022
21 juil. 2022 16h06 HE
|
Gritstone bio
EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced that...
Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank
21 juil. 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 juil. 2022 08h00 HE
|
Gritstone bio
EMERYVILLE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications
10 juin 2022 08h00 HE
|
Gritstone bio
-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and...
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 juin 2022 16h05 HE
|
Gritstone bio
EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...
Gritstone Earns 2022 Great Place to Work Certification™
02 juin 2022 08h00 HE
|
Gritstone bio
EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today...